ALDX

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Aldeyra Therapeutics (ALDX - Research Report) today and set a price target of $15.00. The company's shares closed yesterday at $5.50.Caufield covers the Healthcare sector, focusing on stocks such as Ocuphire Pharma, Eyenovia, and IVERIC bio. According to TipRanks, Caufield has an average return of 18.1% and a 64.29% success rate on recommended stocks. Aldeyra Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.See the top stocks recommended by analysts >>Based on Aldeyra Therapeutics' latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $17.78 million.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-aldeyra-therapeutics-aldx?utm_source=advfn.com&utm_medium=referral